Filing Details

Accession Number:
0001209191-21-017538
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-03 20:37:53
Reporting Period:
2021-03-01
Accepted Time:
2021-03-03 20:37:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1515673 Ultragenyx Pharmaceutical Inc. RARE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1326969 L Camille Bedrosian C/O Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato CA 94949
Evp And Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-01 5,500 $0.00 39,046 No 4 A Direct
Common Stock Acquisiton 2021-03-01 4,636 $0.00 43,682 No 4 A Direct
Common Stock Disposition 2021-03-01 4,543 $138.18 39,139 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right o Buy) Acquisiton 2021-03-01 11,000 $0.00 11,000 $142.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,000 2031-03-01 No 4 A Direct
Footnotes
  1. Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
  2. Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022.
  3. Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.17 to $138.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
  6. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.